Clinical Efficacy Supporting the Role of Intraperitoneal Drug Delivery in the Primary Chemotherapeutic Management of Small-Volume Residual Advanced Ovarian Cancer
- 31 December 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, 3-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal antineoplastic drug delivery: rationale and resultsThe Lancet Oncology, 2003
- A Phase II Trial of Intraperitoneal Cisplatin and Etoposide as Consolidation Therapy in Patients with Stage II–IV Epithelial Ovarian Cancer Following Negative Surgical AssessmentGynecologic Oncology, 1998
- High-Intensity Intravenous Cyclophosphamide and Cisplatin, Interim Surgical Debulking, and Intraperitoneal Cisplatin in Advanced Ovarian Carcinoma: A Pilot Trial with Ten-Year Follow-upGynecologic Oncology, 1997
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavityCritical Reviews in Oncology/Hematology, 1993
- Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapyCancer Chemotherapy and Pharmacology, 1991
- Intracavitary 5-Fluorouracil in Malignant EffusionsArchives of internal medicine (1960), 1965
- Hemisulfur Mustard in the Palliation of Patients with Metastatic Ovarian CarcinomaObstetrics & Gynecology, 1959